Russell Szmulewitz, MD
Enriched profileAssociate Professor of Medicine; Rodin Family Professor in the Wallman Society of Fellows of Medicine; Director, Genitourinary Oncology Program; Associate Director for Clinical Investigation, Comprehensive Cancer Center · University of Chicago Medicine
Russell Szmulewitz is Associate Professor of Medicine; Rodin Family Professor in the Wallman Society of Fellows of Medicine; Director, Genitourinary Oncology Program; Associate Director for Clinical Investigation, Comprehensive Cancer Center at University of Chicago Medicine. OpenAlex indexes 477 publications with 6,193 citations (h-index 35); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 18 Oct 2026
Russell Szmulewitz, M.D., is Associate Professor of Medicine at University of Chicago Medicine. The public record shows 477 publications with 6,193 citations (h-index 35), centered on Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Cancer Genomics and Diagnostics. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 15 companies, 2 NIH-funded awards (2015–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Prostate Cancer Treatment and Research
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 15 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 79.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Geriatric Assessment and Technology Evaluation in Prostate Cancer
Sponsor: University of Chicago
Industry payments
Updated 18 Oct 2026
15 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20252 payments
- Novartis Pharmaceuticals CorporationProgram year20252 payments
- Janssen Scientific Affairs, LLCProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
52.9%Cytochrome P450 17A1 Inhibitor25.4%Abiraterone Acetate100%Part D≥48 patientsAnti-androgens10.6%Erleada68%Nubeqa32%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
42.9%Corticosteroid41.8%Prednisone100%Part D≥81 patientsInsulin Analog1.2%Tresiba Flextouch U-100100%Part D<11 patientsNervous system
3.2%Opioid Agonist1.8%Oxycodone Hcl100%Part D<11 patientsPhenothiazine1.4%Prochlorperazine Maleate100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
2 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:
Congress activity
Updated 18 Oct 2026
96 congress contributions (2005–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study.
Clinical cancer research
Clinical Trial2026 - Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.
Journal of clinical oncology
Guideline2026 - Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.
Clinical cancer research
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03
- 04Prostate Cancer, Version 3.2024Article311 citations2024
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/russell-szmulewitz-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Chicago Pritzker School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗
Editorial & leadership roles
journal and society appointments- Associate Director for Clinical Investigation
University of Chicago Medicine Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.uchicago.edu ↗ - Director
Genitourinary Oncology Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗ - Co-leader
UCCCC Clinical and Experimental Therapeutics Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.uchicago.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗
Media & interviews
press, podcasts and appearances- Featured in The Hinsdalean
Ask an Expert column on prostate cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thehinsdalean.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Wendy Stock, MD
University of Chicago Medicine
Ayodeji Adegunsoye, MD, PhD
University of Chicago Medicine
Gaurav Upadhyay, MD
University of Chicago Medicine
Husam Balkhy, MD
University of Chicago Medicine
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)